Bioinformatics and experimental analyses demonstrate how mir-27a-5p influences Wnt signaling in colorectal cancer, indicating a potential therapeutic target.
Wnt signaling is a key driver of colorectal cancer (CRC) progression, yet directly inhibiting it remains a major challenge. MicroRNAs (miRNAs) are small noncoding RNAs that post-transcriptionally regulate gene expression, thereby modulating oncogenic pathways. However, the role of miR-27a-5p and its underlying mechanisms in CRC remains largely unknown. Bioinformatics analyses and paired clinical CRC specimens were used to evaluate miR-27a-5p expression levels and their association with prognosis. CCK-8, colony formation, wound healing, Transwell invasion, and epithelial–mesenchymal transition (EMT) marker analysis were performed to assess the effects of miR-27a-5p on the malignancy of CRC cells. The potential underlying mechanisms were investigated using dual-luciferase reporter assays, RNA-seq, HPLC-UV, immunoprecipitation/co-immunoprecipitation and immunofluorescence. Xenograft models were used to evaluate the in vivo role of miR-27a-5p in CRC. miR-27a-5p was downregulated in CRC, and its low expression correlated with poorer prognosis. miR-27a-5p directly targeted GFPT2, the rate-limiting enzyme of the hexosamine biosynthetic pathway (HBP), thereby decreasing intracellular uridine 5′-diphosphate N-acetyl-D-glucosamine (UDP-GlcNAc) levels and global protein O-linked β-N-acetylglucosaminylation (O-GlcNAcylation), which in turn reduced β-catenin O-GlcNAcylation, inhibited its nuclear accumulation, and suppressed its transcriptional activity, leading to attenuation of Wnt signaling. Restoring miR-27a-5p expression in CRC cells suppressed proliferation, migration, invasion, and EMT, whereas GFPT2 overexpression or glucosamine supplementation partially reversed the inhibited malignant behaviors. Conversely, β-catenin knockdown attenuated the malignant phenotypes and expression of EMT/Wnt targets induced by miR-27a-5p inhibition, supporting a β-catenin-dependent mechanism. In mouse xenografts, treatment with the O-GlcNAc transferase (OGT) inhibitor OSMI-1 attenuated the accelerated tumor growth driven by miR-27a-5p inhibition, supporting an O-GlcNAcylation-dependent mechanism in vivo. These findings reveal a novel miR-27a-5p–GFPT2–HBP axis that links metabolic reprogramming to Wnt signaling in CRC by suppressing β-catenin activity through the reduction of UDP-GlcNAc-dependent O-GlcNAcylation, thereby restraining CRC progression. This suggests that targeting this axis could attenuate Wnt signaling and slow CRC progression.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: